W. Jared Brewer

ORCID: 0000-0003-2217-2172
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Signaling Pathways in Disease
  • Immune cells in cancer
  • Immune Response and Inflammation
  • CAR-T cell therapy research
  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis
  • Cancer-related molecular mechanisms research
  • Nanowire Synthesis and Applications
  • Trypanosoma species research and implications
  • Single-cell and spatial transcriptomics
  • Electrostatic Discharge in Electronics
  • Platelet Disorders and Treatments
  • Cancer Mechanisms and Therapy
  • Cytokine Signaling Pathways and Interactions
  • Microfluidic and Bio-sensing Technologies

Duke University
2018-2022

The human pathogen Mycobacterium tuberculosis typically causes lung disease but can also disseminate to other tissues. We identified a M. (Mtb) outbreak presenting with unusually high rates of extrapulmonary dissemination and bone disease. found that the causal strain carried an ancestral full-length version type VII-secreted effector EsxM rather than truncated present in modern Mtb lineages. variant exacerbated through enhancement macrophage motility, increased egress macrophages from...

10.1016/j.cell.2022.10.019 article EN cc-by Cell 2022-11-01

Highlights•NFAT signaling induces VEGFA in macrophages downstream of a bacterial glycolipid•NFATC2 is required for angiogenesis induced by mycobacterial trehalose 6,6′-dimycolate•Macrophage-specific inhibition NFAT blocks during infection•In vivo, macrophage-specific reduces burdenSummaryDuring infections, pathogenic mycobacteria manipulate both host immune and stromal cells to establish maintain productive infection. In humans, non-human primates, zebrafish models infection, produce modify...

10.1016/j.celrep.2022.111817 article EN cc-by Cell Reports 2022-12-01

ABSTRACT Adoptive chimeric antigen receptor T-cell (CAR-T) therapy is transformative and approved for hematologic malignancies. It also being developed the treatment of solid tumors, autoimmune disorders, heart disease, aging. Despite unprecedented clinical outcomes, CAR-T other engineered cell therapies face a variety manufacturing safety challenges. Traditional methods, such as lentivirus transduction electroporation, result in random integration or cause significant cellular damage, which...

10.1101/2024.06.25.600671 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-06-27
Coming Soon ...